Potential Interactions Between THC and Desvenlafaxine

Pharmacokinetic and Pharmacodynamic Interactions

THC inhibits several cytochrome P450 enzymes, particularly CYP3A4, CYP2C9, CYP2C19, and others, which could theoretically affect medication metabolism, including desvenlafaxine, in patients taking these substances concurrently 1
Both substances can cause central nervous system effects that may be additive, including dizziness, confusion, somnolence, and fatigue, in patients using THC and desvenlafaxine together 1
The serotonergic effects of desvenlafaxine could theoretically interact with THC's effects on mood and cognition, though specific data on this combination is limited, and may affect patients with a history of mood disorders 2
Cannabis products have variable THC and CBD content, making drug interactions unpredictable and difficult to standardize, and potentially affecting patients using these products with desvenlafaxine 1, 3

The American College of Physicians recommends starting cannabis products at the lowest possible dose and increasing slowly with sufficient time between doses to gauge effects, in order to minimize potential interactions with desvenlafaxine 1
Clinicians should be vigilant for signs of increased adverse effects, particularly dizziness and confusion, changes in blood pressure, and mood alterations, in patients taking THC and desvenlafaxine concurrently 1
Avoiding high-fat meals when taking oral cannabis products is recommended, as this significantly increases cannabinoid absorption and may exacerbate drug interactions with desvenlafaxine 1

Elderly patients and those with hepatic impairment may be at higher risk for adverse effects due to reduced drug clearance, and should be monitored closely when taking THC and desvenlafaxine together 1
Patients with a history of cardiovascular issues should be monitored more closely, as both substances can affect heart rate and blood pressure, and may increase the risk of cardiovascular events 1

Clinicians should monitor for increased side effects when initiating or changing the dose of either substance, in order to minimize potential interactions and adverse effects 1
Being aware that adulteration of cannabis products with synthetic cannabinoid receptor agonists can lead to unpredictable clinical outcomes and exacerbate potential drug interactions with desvenlafaxine is crucial, and may affect patients using these products 4